Common use of Plans and Reports Clause in Contracts

Plans and Reports. (a) At least [...***...] prior to the first Launch Date of the Product in the Territory or, if the Parties reasonably expect the first Launch Date of the Product in any country in the Territory to be less than [...***...] from the Effective Date, then as soon as is practicable with respect to such country in the Territory, Licensee shall prepare and provide to Allergan and the JCC a written pre-Commercialization plan (the "Pre-Commercialization Plan") describing in detail the planned Commercialization of the Product in the Territory for the [...***...] period following such Launch Date. The Pre-Commercialization Plan shall include the following information with respect to the Product in the Territory: a review of core markets, key drivers, competitors and key environmental issues, brand vision and strategy, brand positioning, value proposition for payers, forecast, lifecycle management and franchise maximization plans, resource plans (including sales and marketing costs), field force, advertising and promotion and medical affairs activities and expenses. The JCC shall review and approve the Pre-Commercialization Plan and any and all amendments thereto. (b) Within [...***...] after the Effective Date, Licensee shall prepare and provide to Allergan with a business plan, marketing plan and sales forecast (such plans and forecast, as amended and updated from time to time in accordance with this Section 4.3(b), the "Annual Plan") to cover in detail the Development and Commercialization of the Product in the Territory for the remainder of the first Calendar Year and the next full Calendar Year. The Annual Plan shall include the following information with respect to the Product in the Territory: brand vision and strategy (including positioning branding and key messaging), market and competitive map (including main opportunities for brand, key issues to address, market segmentation, business insight and market research plans), strategic communications (including global congresses, publication plans, ad boards/key opinion leader advocacy, Phase IV plans, medical education programs and public relations), price and market access considerations and plans, sales forecast (including sales, market share and days of therapy) and expenses (including sales force, advertising and promotion). Thereafter, Licensee shall, on an annual basis prepare and provide to Allergan an updated Annual Plan to cover the forthcoming Calendar Year. The JCC shall review and approve the Annual Plan and any and all amendments thereto. 14 (c) Within [...***...] after each Calendar Quarter, Licensee shall provide Allergan with (i) unit and sales volume reports of the Product with [...***...] rolling sales forecasts and competing product performance data; (ii) inventory reports of the Product by SKU; and (iii) sales reports of the Product in the Territory.

Plans and Reports. (a) At least [...***...redacted in accordance with Section 12.2(3) of National Instrument 51-102] prior to the first Launch Date of the Product in the Territory or, if the Parties reasonably expect the first Launch Date of the Product in any country in the Territory to be less than [...***...redacted in accordance with Section 12.2(3) of National Instrument 51-102] from the Effective Date, then as soon as is practicable with respect to such country in the Territory, Licensee shall prepare and provide to Allergan and the JCC a written pre-Commercialization plan (the "“Pre-Commercialization Plan"”) describing in detail the planned Commercialization of the Product in the Territory for the [...***...redacted in accordance with Section 12.2(3) of National Instrument 51-102] period following such Launch Date. The Pre-Commercialization Plan shall include the following information with respect to the Product in the Territory: a review of core markets, key drivers, competitors and key environmental issues, brand vision and strategy, brand positioning, value proposition for payers, forecast, lifecycle management and franchise maximization plans, resource plans (including sales and marketing costs), field force, advertising and promotion and medical affairs activities and expenses. The JCC shall review and approve the Pre-Commercialization Plan and any and all amendments thereto. (b) Within [...***...redacted in accordance with Section 12.2(3) of National Instrument 51-102] after the Effective Date, Licensee shall prepare and provide to Allergan with a business plan, marketing plan and sales forecast (such plans and forecast, as amended and updated from time to time in accordance with this Section 4.3(b), the "“Annual Plan"”) to cover in detail the Development and Commercialization of the Product in the Territory for the remainder of the first Calendar Year and the next full Calendar Year. The Annual Plan shall include the following information with respect to the Product in the Territory: brand vision and strategy (including positioning branding and key messaging), market and competitive map (including main opportunities for brand, key issues to address, market segmentation, business insight and market research plans), strategic communications (including global congresses, publication plans, ad boards/key opinion leader advocacy, Phase IV plans, medical education programs and public relations), price and market access considerations and plans, sales forecast (including sales, market share and days of therapy) and expenses (including sales force, advertising and promotion). Thereafter, Licensee shall, on an annual basis prepare and provide to Allergan an updated Annual Plan to cover the forthcoming Calendar Year. The JCC shall review and approve the Annual Plan and any and all amendments thereto. 14 . (c) Within [...***...redacted in accordance with Section 12.2(3) of National Instrument 51-102] after each Calendar Quarter, Licensee shall provide Allergan with (i) unit and sales volume reports of the Product with [...***...redacted in accordance with Section 12.2(3) of National Instrument 51-102] rolling sales forecasts and competing product performance data; (ii) inventory reports of the Product by SKU; and (iii) sales reports of the Product in the Territory.